Free Trial

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$35.60 -1.62 (-4.35%)
As of 04:00 PM Eastern

CRSP vs. EXEL, NBIX, MRNA, QGEN, TECH, RGEN, HALO, RVMD, ADMA, and KRYS

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Exelixis (EXEL), Neurocrine Biosciences (NBIX), Moderna (MRNA), Qiagen (QGEN), Bio-Techne (TECH), Repligen (RGEN), Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.

CRISPR Therapeutics vs.

Exelixis (NASDAQ:EXEL) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Exelixis has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exelixis$2.17B4.70$521.27M$1.7720.88
CRISPR Therapeutics$35M91.84-$366.25M-$4.52-8.23

In the previous week, CRISPR Therapeutics had 15 more articles in the media than Exelixis. MarketBeat recorded 55 mentions for CRISPR Therapeutics and 40 mentions for Exelixis. Exelixis' average media sentiment score of 1.44 beat CRISPR Therapeutics' score of 0.17 indicating that Exelixis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exelixis
25 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
CRISPR Therapeutics
9 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Neutral

Exelixis received 139 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 68.58% of users gave Exelixis an outperform vote while only 64.40% of users gave CRISPR Therapeutics an outperform vote.

CompanyUnderperformOutperform
ExelixisOutperform Votes
622
68.58%
Underperform Votes
285
31.42%
CRISPR TherapeuticsOutperform Votes
483
64.40%
Underperform Votes
267
35.60%

Exelixis has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Exelixis currently has a consensus price target of $37.59, indicating a potential upside of 1.73%. CRISPR Therapeutics has a consensus price target of $71.75, indicating a potential upside of 92.77%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis
2 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.47
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.50

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 2.8% of Exelixis shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Exelixis has a net margin of 24.04% compared to CRISPR Therapeutics' net margin of -981.54%. Exelixis' return on equity of 23.52% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Exelixis24.04% 23.52% 17.95%
CRISPR Therapeutics -981.54%-18.46%-15.79%

Summary

Exelixis beats CRISPR Therapeutics on 12 of the 18 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.21B$2.84B$5.33B$8.42B
Dividend YieldN/A1.92%4.99%4.19%
P/E Ratio-8.5230.3926.7319.79
Price / Sales91.84456.28407.30120.35
Price / CashN/A168.6838.3134.62
Price / Book1.653.016.734.50
Net Income-$366.25M-$72.17M$3.22B$248.10M
7 Day Performance8.62%2.78%2.15%5.62%
1 Month Performance-4.10%6.45%7.35%12.11%
1 Year Performance-33.19%-29.30%14.38%6.25%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
3.0511 of 5 stars
$35.60
-4.4%
$71.75
+101.5%
-33.1%$3.07B$35M-8.15473Analyst Revision
EXEL
Exelixis
4.0257 of 5 stars
$40.11
+1.3%
$37.59
-6.3%
+73.7%$11.09B$2.17B22.731,220Analyst Forecast
Options Volume
News Coverage
Positive News
Gap Up
NBIX
Neurocrine Biosciences
4.931 of 5 stars
$110.73
+1.0%
$160.90
+45.3%
-14.2%$10.98B$2.36B33.721,200
MRNA
Moderna
4.4527 of 5 stars
$27.92
+1.1%
$53.95
+93.2%
-79.7%$10.79B$3.14B-3.013,900
QGEN
Qiagen
4.0396 of 5 stars
$42.93
-0.5%
$48.42
+12.8%
-2.4%$9.54B$1.98B119.546,030Earnings Report
TECH
Bio-Techne
4.8569 of 5 stars
$50.20
-0.6%
$81.14
+61.6%
-37.0%$7.94B$1.20B50.703,000Earnings Report
Dividend Announcement
Buyback Announcement
RGEN
Repligen
4.9222 of 5 stars
$141.16
-0.3%
$173.25
+22.7%
-19.5%$7.93B$650.43M-276.812,020Positive News
HALO
Halozyme Therapeutics
4.9733 of 5 stars
$60.75
-0.7%
$62.89
+3.5%
+15.2%$7.51B$1.02B17.72390Analyst Downgrade
News Coverage
RVMD
Revolution Medicines
4.3482 of 5 stars
$40.25
-1.2%
$66.67
+65.7%
+7.5%$7.50B$742,000.00-11.22250Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
Positive News
ADMA
ADMA Biologics
3.7069 of 5 stars
$23.86
+1.4%
$22.50
-5.7%
+126.2%$5.71B$426.45M85.75530Earnings Report
Analyst Revision
KRYS
Krystal Biotech
4.8813 of 5 stars
$163.46
-1.6%
$222.71
+36.3%
-13.1%$4.73B$290.52M54.73210Analyst Revision

Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners